We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Expert Opinion / Commentary · June 24, 2021

Adjuvant—Not Concurrent—Temozolomide Upped Overall Survival in 1p/19q Non–Co-Deleted Anaplastic Glioma: Commentary on the CATNON Trial

Written by
Manmeet Ahluwalia MD, FACP, MBA
Minesh P. Mehta MD, FASTRO


Further Reading